AREV Life Sciences (CSE: AREV) (OTC: AREVF) is dedicated to delivering therapeutic interventions to public health through discovery, innovation and successful industry collaborations. Its leadership team is focused on driving discovery programs for clinical complexities demonstrated by malnutrition, the inflammatory response system and viral infectious diseases. “AREV’s business model leverages the core competency of producing proprietary compounds through its innovative extraction methodologies, scientific advisory board (‘SAB’), experienced staff, and executive leadership to drive its product pipeline,” reads a recent article discussing the company. “AREV’s strategy is to generate revenue from selling its branded products via its online technology platform, Medicine Merchant(TM), an enterprise marketing platform built to enable consumers to have access to novel therapeutic approaches to human nutrition, endemic diseases and neglected chronic related co-morbidities. The company also expects to generate revenue from toll processing and government procurement of its products that address malnutrition and related health issues.”
To view the full article, visit https://ibn.fm/3kl7q
About AREV Life Sciences Global Corp.
AREV Life Sciences is a fully integrated, publicly traded, early stage life science enterprise dedicated to delivering therapeutic interventions to public health through extraction of unique compounds, discovery, innovation and successful collaborations. The company’s leadership drives discovery programs for clinical complexities presented by malnutrition, viral infectious diseases and the inflammatory response system. AREV is invested in commercial innovations in phytomedicinal discoveries of small molecule antivirals and for related neglected chronic co-morbidities and innovations in human nutrition. AREV is dedicated to designing and delivering innovation in rational drug design, driven by presenting global epidemiological characteristics of multiple challenges to international human and animal health. AREV is a member of both BIOTECanada and The Biotechnology Innovation Organization (“BIO”). For more information, visit www.AREVLifeSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to AREVF are available in the company’s newsroom at https://ibn.fm/AREVF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.